Inflammatory Bowel Disease Research Center, Department of Gastroenterology, Guangdong Province Key Laboratory of Major Obstetric Disease, Province Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Front Immunol. 2024 Feb 22;15:1322054. doi: 10.3389/fimmu.2024.1322054. eCollection 2024.
Inflammatory bowel disease (IBD) is a chronic, recurrent gastrointestinal disorder with elusive etiology. Interleukin-12 (IL-12) and IL-23 have emerged as key proinflammatory mediators/cytokines in IBD pathogenesis. Ustekinumab (UST), targeting IL-12 and IL-23, has demonstrated promising efficacy and safety in the treatment of IBD. Recently, UST has become increasingly favored as a potential first-line treatment option. This review delineates UST's mechanism of action, its clinical applications in IBD, including the response rates, strategies for dose optimization for case of partial or lost response, and potential adverse events. This review aims to offer a comprehensive understanding of UST's role as a therapeutic option in IBD management.
炎症性肠病（IBD）是一种慢性、复发性胃肠道疾病，病因难以捉摸。白细胞介素-12（IL-12）和白细胞介素-23（IL-23）已成为 IBD 发病机制中的关键促炎介质/细胞因子。靶向 IL-12 和 IL-23 的乌司奴单抗（UST）在治疗 IBD 方面显示出了有前景的疗效和安全性。最近，UST 作为一种潜在的一线治疗选择越来越受到青睐。本综述阐述了 UST 的作用机制，以及其在 IBD 中的临床应用，包括其应答率、针对部分或应答丧失情况的剂量优化策略，以及潜在的不良反应。本综述旨在全面了解 UST 在 IBD 管理中的治疗选择作用。
